New drug cocktail aims to shrink Hard-to-Treat breast tumors
NCT ID NCT05227664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two experimental drugs (AK117 and AK112) to standard chemotherapy can shrink tumors in people with advanced triple-negative breast cancer that hasn't been treated yet. About 120 participants will receive the combination. The main goals are to see how many respond and what side effects occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
Changsha, China
-
Xiangyang Central Hospital
Xiangyang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- New drug targets Hard-to-Treat cancers in japanese patients
- Could a simple capsule beat chemo fatigue? new trial aims to find out
- Experimental cell therapy targets multiple cancers in early trial
- Scientists hunt for clues to better treat aggressive breast cancer
- New pill takes on tough breast cancer in first human trial